Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative)

v3.22.1
Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative) - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Dec. 31, 2020
Research And Development Expenses $ 3,600,000.0 $ 3,900,000.0    
Cash And Cash Equivalent 23,732,379 $ 33,061,711 $ 20,581,313 $ 19,444,737
Deferred Revenue 10,000,000   12,512  
Accounts Receivable $ 72,371   $ 12,510  
Warrants And Options [Member]        
Potentially Dilutive Securities Excluded From The Computation Of Eps 6,346,268      
Money Market Funds [Member]        
Cash And Cash Equivalent $ 10,200,000.0